Effect of Nocturnal Oxygen Therapy on Daytime Pulmonary Hemodynamics in Patients With Chronic Obstructive Pulmonary Disease Traveling to Altitude: A Randomized Controlled Trial
Open Access
- 7 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Physiology
Abstract
Introduction: We investigated whether nocturnal oxygen therapy (NOT) mitigates the increase of pulmonary artery pressure in patients during daytime with chronic obstructive pulmonary disease (COPD) traveling to altitude. Methods: Patients with COPD living below 800 m underwent examinations at 490 m and during two sojourns at 2,048 m (with a washout period of 2 weeks < 800 m between altitude sojourns). During nights at altitude, patients received either NOT (3 L/min) or placebo (ambient air 3 L/min) via nasal cannula according to a randomized crossover design. The main outcomes were the tricuspid regurgitation pressure gradient (TRPG) measured by echocardiography on the second day at altitude (under ambient air) and various other echocardiographic measures of the right and left heart function. Patients fulfilling predefined safety criteria were withdrawn from the study. Results: Twenty-three COPD patients [70% Global Initiative for Chronic Obstructive Lung Disease (GOLD) II/30% GOLD III, mean ± SD age 66 ± 5 years, FEV1 54% ± 13% predicted] were included in the per-protocol analysis. TRPG significantly increased when patients traveled to altitude (from low altitude 21.7 ± 5.2 mmHg to 2,048 m placebo 27.4 ± 7.3 mmHg and 2,048 m NOT 27.8 ± 8.3 mmHg) difference between interventions (mean difference 0.4 mmHg, 95% CI −2.1 to 3.0, p = 0.736). The tricuspid annular plane systolic excursion was significantly higher after NOT vs. placebo [2.6 ± 0.6 vs. 2.3 ± 0.4 cm, mean difference (95% confidence interval) 0.3 (0.1 − 0.5) cm, p = 0.005]. During visits to 2,048 m until 24 h after descent, eight patients (26%) using placebo and one (4%) using NOT had to be withdrawn because of altitude-related adverse health effects (p < 0.001). Conclusion: In lowlanders with COPD remaining free of clinically relevant altitude-related adverse health effects, changes in daytime pulmonary hemodynamics during a stay at high altitude were trivial and not modified by NOT. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02150590.This publication has 30 references indexed in Scilit:
- Long-term Effect of Vasodilator Therapy in Pulmonary Hypertension due to COPD: A Retrospective AnalysisLung, 2014
- Right Ventricular Morphology and Function in Chronic Obstructive Pulmonary Disease Patients Living at High AltitudeHeart, Lung and Circulation, 2013
- Acute Hemodynamic Responses to Supplemental Oxygen and Their Prognostic Implications in Pulmonary HypertensionRespiration, 2012
- Association of Chronic Mountain Sickness With Abnormal Pulmonary MicrocirculationSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2010
- Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography: Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of EchocardiographyJournal of the American Society of Echocardiography, 2010
- Right Heart Function in COPDSeminars in Respiratory and Critical Care Medicine, 2010
- Genetic Polymorphisms of the Serotonin Transporter, but Not the 2a Receptor or Nitric Oxide Synthetase, Are Associated with Pulmonary Hypertension in Chronic Obstructive Pulmonary DiseaseRespiration, 2009
- Hyperoxia prevents exercise‐induced intrapulmonary arteriovenous shunt in healthy humansJournal Of Physiology-London, 2008
- New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery PressureSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2004
- Hemodynamic correlates of exercise function in patients with primary pulmonary hypertensionJournal of the American College of Cardiology, 1991